Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Ocular Therapeutix Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
OCUL
Nasdaq
8731
https://www.ocutx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Ocular Therapeutix Inc
Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)
- Mar 26th, 2024 11:30 am
Q4 2023 Clearside Biomedical Inc Earnings Call
- Mar 13th, 2024 10:38 am
Wall Street Analysts Think Ocular Therapeutix (OCUL) Could Surge 34.74%: Read This Before Placing a Bet
- Mar 12th, 2024 1:55 pm
Ocular Therapeutix Inc Reports Growth Amidst Strategic Shifts
- Mar 11th, 2024 9:32 pm
Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates
- Mar 11th, 2024 9:25 pm
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results
- Mar 11th, 2024 8:05 pm
Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024
- Mar 5th, 2024 12:30 pm
Criteo, Ocular Therapeutix, and More Stocks See Action From Activist Investors
- Mar 1st, 2024 11:30 pm
Should You Buy Ocular Therapeutix (OCUL) Ahead of Earnings?
- Feb 29th, 2024 1:52 pm
Are You Looking for a Top Momentum Pick? Why Ocular Therapeutix (OCUL) is a Great Choice
- Feb 26th, 2024 5:00 pm
Ocular Therapeutix (OCUL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Feb 26th, 2024 3:00 pm
3 Stocks to Buy That Are Up 100% or More in 2024
- Feb 25th, 2024 7:02 pm
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer
- Feb 22nd, 2024 12:32 pm
Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement
- Feb 22nd, 2024 12:31 pm
Ocular Therapeutix™ Announces Board of Directors and Leadership Updates
- Feb 22nd, 2024 12:30 pm
Wall Street Analysts Believe Ocular Therapeutix (OCUL) Could Rally 64.63%: Here's is How to Trade
- Feb 21st, 2024 2:55 pm
AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis
- Feb 19th, 2024 2:00 pm
Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer
- Feb 15th, 2024 1:00 pm
Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD
- Feb 13th, 2024 12:37 pm
Ocular Therapeutix (OCUL) Surges 12.9%: Is This an Indication of Further Gains?
- Feb 12th, 2024 11:27 am
Scroll